The US Food and Drug Administration (FDA) has debuted new draft guidance that aims to streamline and expedite the biosimilar development process. The regulatory framework has been designed to reduce ...
Please provide your email address to receive an email when new articles are posted on . An FDA draft guidance nixing the requirement for biosimilar manufacturers to conduct comparative efficacy ...
If the Trump White House is serious about its push to make medicines more affordable, it should ensure CMS officials never ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results